Baker Bros. Advisors LP Achilles Therapeutics PLC Transaction History
Baker Bros. Advisors LP
- $7.52 Billion
- Q2 2024
A detailed history of Baker Bros. Advisors LP transactions in Achilles Therapeutics PLC stock. As of the latest transaction made, Baker Bros. Advisors LP holds 1,108,767 shares of ACHL stock, worth $1.09 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
1,108,767
Previous 1,208,775
8.27%
Holding current value
$1.09 Million
Previous $1.51 Million
39.8%
% of portfolio
0.01%
Previous 0.02%
Shares
5 transactions
Others Institutions Holding ACHL
# of Institutions
29Shares Held
22.2MCall Options Held
0Put Options Held
0-
Syncona Portfolio LTD Guernsey, Channel Islands, X011.1MShares$10.9 Million10.58% of portfolio
-
Fcpm Iii Services B.V. Naarden, P72.39MShares$2.34 Million0.29% of portfolio
-
Redmile Group, LLC San Francisco, CA1.61MShares$1.58 Million0.09% of portfolio
-
Vestal Point Capital, LP New York, NY1.5MShares$1.47 Million0.09% of portfolio
-
Ikarian Capital, LLC Dallas, TX1.44MShares$1.41 Million0.48% of portfolio
About Achilles Therapeutics plc
- Ticker ACHL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,774,000
- Market Cap $40M
- Description
- Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in ...